Title: <i>Helicobacter pylori</i> ‐induced miR‐135b‐5p promotes cisplatin resistance in gastric cancer
Abstract: The FASEB JournalVolume 33, Issue 1 p. 264-274 ResearchFree to Read Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer Linlin Shao, Linlin Shao Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USA These authors contributed equally to this work.Search for more papers by this authorZheng Chen, Zheng Chen Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA These authors contributed equally to this work.Search for more papers by this authorMohammed Soutto, Mohammed Soutto Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USASearch for more papers by this authorShoumin Zhu, Shoumin Zhu Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USASearch for more papers by this authorHeng Lu, Heng Lu Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USASearch for more papers by this authorJudith Romero-Gallo, Judith Romero-Gallo Division of Gastroenterology, Hematology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USASearch for more papers by this authorRichard Peek, Richard Peek Division of Gastroenterology, Hematology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USASearch for more papers by this authorShutian Zhang, Corresponding Author Shutian Zhang [email protected] Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Correspondence: Beijing Friendship Hospital, Capital Medical University, 95# Yong'an Rd., Xi'cheng District, Beijing, China, 10050. E-mail: [email protected] Correspondence: University of Miami Miller School of Medicine, 1600 NW 10th Ave., Miami, FL 33136-1015, USA. E-mail: [email protected] for more papers by this authorWael El-Rifai, Corresponding Author Wael El-Rifai [email protected] Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USA Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA Correspondence: Beijing Friendship Hospital, Capital Medical University, 95# Yong'an Rd., Xi'cheng District, Beijing, China, 10050. E-mail: [email protected] Correspondence: University of Miami Miller School of Medicine, 1600 NW 10th Ave., Miami, FL 33136-1015, USA. E-mail: [email protected] for more papers by this author Linlin Shao, Linlin Shao Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USA These authors contributed equally to this work.Search for more papers by this authorZheng Chen, Zheng Chen Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA These authors contributed equally to this work.Search for more papers by this authorMohammed Soutto, Mohammed Soutto Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USASearch for more papers by this authorShoumin Zhu, Shoumin Zhu Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USASearch for more papers by this authorHeng Lu, Heng Lu Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USASearch for more papers by this authorJudith Romero-Gallo, Judith Romero-Gallo Division of Gastroenterology, Hematology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USASearch for more papers by this authorRichard Peek, Richard Peek Division of Gastroenterology, Hematology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USASearch for more papers by this authorShutian Zhang, Corresponding Author Shutian Zhang [email protected] Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Correspondence: Beijing Friendship Hospital, Capital Medical University, 95# Yong'an Rd., Xi'cheng District, Beijing, China, 10050. E-mail: [email protected] Correspondence: University of Miami Miller School of Medicine, 1600 NW 10th Ave., Miami, FL 33136-1015, USA. E-mail: [email protected] for more papers by this authorWael El-Rifai, Corresponding Author Wael El-Rifai [email protected] Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USA Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA Correspondence: Beijing Friendship Hospital, Capital Medical University, 95# Yong'an Rd., Xi'cheng District, Beijing, China, 10050. E-mail: [email protected] Correspondence: University of Miami Miller School of Medicine, 1600 NW 10th Ave., Miami, FL 33136-1015, USA. E-mail: [email protected] for more papers by this author First published: 09 July 2018 https://doi.org/10.1096/fj.201701456RRCitations: 1 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat ABSTRACT Helicobacter pylori infection is a major risk factor for the development of gastric cancer. Aberrant expression of microRNAs is strongly implicated in gastric tumorigenesis; however, their contribution in response to H. pylori infection has not been fully elucidated. In this study, we evaluated the expression of miR-135b-5p and its role in gastric cancer. We describe the overexpression of miR-135b-5p in human gastric cancer tissue samples compared with normal tissue samples. Furthermore, we found that miR-135b-5p is also up-regulated in gastric tumors from the trefoil factor 1-knockout mouse model. Infection with H. pylori induced the expression of miR-135b-5p in the in vitro and in vivo models. miR-135b-5p induction was mediated by NF-κB. Treatment of gastric cancer cells with TNF-α induced miR-135b-5p in a NF-κB–dependent manner. Mechanistically, we found that miR-135b-5p targets Krüppel-like factor 4 (KLF4) and binds to its 3′ UTR, leading to reduced KLF4 expression. Functionally, high levels of miR-135b-5p suppress apoptosis and induce cisplatin resistance. Our results uncovered a mechanistic link between H. pylori infection and miR-135b-5p-KLF4, suggesting that targeting miR-135b-5p could be a potential therapeutic approach to circumvent resistance to cisplatin.—Shao, L., Chen, Z., Soutto, M., Zhu, S., Lu, H., Romero-Gallo, J., Peek, R., Zhang, S., El-Rifai, W. Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer. FASEB J. 33, 264–274 (2019). www.fasebj.org Citing Literature Volume33, Issue1January 2019Pages 264-274 RelatedInformation